MRSA Hospital Infections Can Cost $61,000 Each to Treat

A new study indicates that antibiotic-resistant hospital infections can cost hospitals $61,000 to treat and may increase the risk of death for patients seven-fold.

Researchers say that the results of the study, published in the latest issue of the Public Library of Science journal, PLoS One, show that even infection prevention techniques considered prohibitively expensive would actually save hospitals money when compared to what they spend to treat hospital-acquired MRSA infections. Such measures would also save lives and prevent injuries and severe illnesses, in addition to saving money, said researchers from Duke University.

Methicillin-resistant Staphyloccus aureus (MRSA) infections, also known as “superbug” infections, have been steadily growing in the U.S. over the last decade. According to the U.S. Centers for Disease Control and Prevention (CDC), there are more than 2 million hospital infections acquired each year, resulting in about 90,000 deaths annually. Another 1.5 million long term care and nursing home infections occur every year. MRSA, which resists treatment by many antibiotics, has accounted for more than 60 percent of hospital staph infections in recent years.

Did You Know?

Change Healthcare Data Breach Impacts Millions of Customers

A massive Change Healthcare data breach exposed the names, social security numbers, medical and personal information of potentially 100 million Americans, which have now been released on the dark web. Lawsuits are being pursued to obtain financial compensation.

Learn More

A study last month in the CDC’s Emerging Infectious Diseases medical journal indicated that there has been a 90% increase in MRSA infections since 1999. Researchers in that study said that MRSA may be responsible for 20,000 deaths in the U.S. annually.

The latest study looked at the impact of surgical site MRSA infections in hospitals and examined the records of more than 140,000 surgeries performed between 1998 and 2003. The researchers found that surgical site infections (SSI) due to MRSA led to $19 million in additional spending by the hospitals examined in the study, costing about $61,000 in additional spending for each case of infection.

In addition to cost, the researchers said that patients with MRSA infections were seven times more likely to die within 90 days of their surgery and 35 times more likely to be readmitted to the hospital. MRSA infections also resulted in an average of about three weeks of additional hospitalization, according to the study’s results.

“Our findings confirm that SSIs due to MRSA lead to significant patient suffering and provide quantitative estimates of the staggering costs of these infections,” researchers said in their conclusions. “If an intervention costs less than $61,000 and leads to the prevention of only one SSI due to MRSA, then this intervention will likely be cost effective for the institution.”

The calculations done by the researchers did not include the legal cost of such infections, which have been rising steadily for hospitals. In recent years, there has been an increasing number of hospital infection lawsuits filed throughout the United States, as experts believe that most of these potentially life-threatening infections can be prevented if steps are taken by the hospital and staff.

These steps could include improved methods of handling catheter during insertion, leaving them in for shorter periods and improved hygiene. Many hospitals have instituted new rules to ensure that hands are washed and increased efforts are being taken to keep areas lie the ICU more sterile and catheters clean.

1 Comments

  • JamesFebruary 8, 2016 at 5:22 am

    I find it so very frustrating that a product I first began working with when I was hospitalized for MRSA five years ago, has since been approved by the EPA to be used in hospitals and could really eliminate MRSA in a relatively short period of time. This will work for almost all HAIs.

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

BioZorb Lawsuit Indicates Recalled Tissue Marker Migrated After It Failed To Absorb, Resulting in Severe Pain and Surgical Removal
BioZorb Lawsuit Indicates Recalled Tissue Marker Migrated After It Failed To Absorb, Resulting in Severe Pain and Surgical Removal (Posted yesterday)

Days after the FDA announced a BioZorb recall, an Arkansas woman has filed a lawsuit, indicating that her BioZorb tissue marker migrated out of position, causing pain and disfigurement, instead of harmlessly absorbing into the body as advertised.

Judge Outlines Suboxone Tooth Decay Lawsuit Census Requirements
Judge Outlines Suboxone Tooth Decay Lawsuit Census Requirements (Posted 2 days ago)

To help the parties identify Suboxone lawsuits that can be used as representative samples in early bellwether trials, the federal judge presiding over the litigation has directed the parties to conduct a census of all tooth decay claims.